Literature DB >> 14998334

Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes.

C Andrew Boswell1, Xiankai Sun, Weijun Niu, Gary R Weisman, Edward H Wong, Arnold L Rheingold, Carolyn J Anderson.   

Abstract

The increased use of copper radioisotopes in radiopharmaceutical applications has created a need for bifunctional chelators (BFCs) that form stable radiocopper complexes and allow covalent attachment to biological molecules. The chelators most commonly utilized for labeling copper radionuclides to biomolecules are analogues of 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA); however, recent reports have communicated the instability of the radio-Cu(II)-TETA complexes in vivo. A class of bicyclic tetraazamacrocycles, the ethylene "cross-bridged" cyclam (CB-cyclam) derivatives, form highly kinetically stable complexes with Cu(II) and therefore may be less susceptible to transchelation than their nonbridged analogues in vivo. Herein we report results on the relative biological stabilities and identification of the resulting radiolabeled metabolites of a series of (64)Cu-labeled macrocyclic complexes. Metabolism studies in normal rat liver have revealed that the (64)Cu complex of 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane ((64)Cu-CB-TE2A) resulted in significantly lower values of protein-associated (64)Cu than (64)Cu-TETA [13 +/- 6% vs 75 +/- 9% at 4 h]. A similar trend was observed for the corresponding cyclen derivatives, with the (64)Cu complex of 4,10-bis(carboxymethyl)-1,4,7,10-tetraazabicyclo[5.5.2]tetradecane ((64)Cu-CB-DO2A) undergoing less transchelation than the (64)Cu complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid ((64)Cu-DOTA) [61 +/- 14% vs 90.3 +/- 0.5% protein associated (64)Cu at 4 h]. These data indicate that the structurally reinforcing cross-bridge enhances in vivo stability by reducing metal loss to protein in both the cyclam and cyclen cross-bridged (64)Cu complexes and that (64)Cu-CB-TE2A is superior to (64)Cu-CB-DO2A in that regard. These findings further suggest that a bifunctional chelator derivative of CB-TE2A is a highly desirable alternative for labeling copper radionuclides to biological molecules for diagnostic imaging and targeted radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14998334     DOI: 10.1021/jm030383m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  157 in total

1.  Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.

Authors:  Yunjun Guo; Riccardo Ferdani; Carolyn J Anderson
Journal:  Bioconjug Chem       Date:  2012-06-18       Impact factor: 4.774

2.  Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer.

Authors:  Dijie Liu; Douglas Overbey; Lisa D Watkinson; Charles J Smith; Said Daibes-Figueroa; Timothy J Hoffman; Leonard R Forte; Wynn A Volkert; Michael F Giblin
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

3.  In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.

Authors:  Jeffrey M Craft; Ravindra A De Silva; Kimberly A Lears; Rebecca Andrews; Kexian Liang; Samuel Achilefu; Buck E Rogers
Journal:  Nucl Med Biol       Date:  2012-01-20       Impact factor: 2.408

4.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.

Authors:  Maggie S Cooper; Michelle T Ma; Kavitha Sunassee; Karen P Shaw; Jennifer D Williams; Rowena L Paul; Paul S Donnelly; Philip J Blower
Journal:  Bioconjug Chem       Date:  2012-04-13       Impact factor: 4.774

Review 5.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

6.  Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.

Authors:  Zhaofei Liu; Bing Jia; Huiyun Zhao; Xiaoyuan Chen; Fan Wang
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

7.  Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT.

Authors:  Sabrina H L Hoffmann; Andreas Maurer; Dorothea I Reck; Gerald Reischl; Bernd J Pichler; Manfred Kneilling; Christoph M Griessinger
Journal:  J Vis Exp       Date:  2017-04-29       Impact factor: 1.355

8.  Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Authors:  Lihui Wei; Yubin Miao; Fabio Gallazzi; Thomas P Quinn; Michael J Welch; Amy L Vāvere; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2007-09-04       Impact factor: 2.408

9.  In vivo molecular imaging of thrombosis and thrombolysis using a fibrin-binding positron emission tomographic probe.

Authors:  Ilknur Ay; Francesco Blasi; Tyson A Rietz; Nicholas J Rotile; Sreekanth Kura; Anna Liisa Brownell; Helen Day; Bruno L Oliveira; Richard J Looby; Peter Caravan
Journal:  Circ Cardiovasc Imaging       Date:  2014-04-28       Impact factor: 7.792

10.  Fibrin-targeted PET probes for the detection of thrombi.

Authors:  Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan
Journal:  Mol Pharm       Date:  2013-01-30       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.